What it is

MOTS-c is a short peptide encoded by mitochondrial DNA, specifically within the 12S rRNA region of the mitochondrial genome. It is part of a broader class of “mitochondrial-derived peptides”, a category that complicates the usual mental model of peptides as something made from nuclear genes, processed, and secreted like conventional hormones.

Because it is encoded in the mitochondrial genome and reported in circulating blood, MOTS-c is often framed as a metabolism-linked signal that sits closer to cellular energy status than many other peptide stories.

Why people use it

Online, MOTS-c is typically positioned as a “metabolic” peptide rather than an appetite peptide. People talk about it in the language of energy, endurance, body composition, and insulin sensitivity. That framing overlaps with how the academic literature discusses MOTS-c, but it is a long jump from mechanistic plausibility to reliable human outcomes.

A practical note for the field guide: the name MOTS-c is used in research papers to describe an endogenous peptide. Consumer products marketed as “MOTS-c” are a separate quality and identity question.

History and origin

MOTS-c entered the modern literature as part of work describing mitochondrial-derived peptides as regulators of metabolic biology. In a widely cited 2015 paper, researchers reported that MOTS-c could influence metabolic homeostasis in experimental systems.

Subsequent work expanded the hypothesis from “a peptide made by mitochondria exists” to “it can act as a stress-responsive signal”, including reports that MOTS-c can affect nuclear gene expression programs under metabolic stress.

How it works

Mechanistically, MOTS-c is usually discussed as a stress and metabolism signal. Proposed pathways include activation of AMPK-related programs and downstream shifts in how cells handle glucose and fuel selection, with a special focus on skeletal muscle and whole-body insulin sensitivity.

At a plain-language level, the story is that mitochondria may produce small peptides that behave like internal status updates. Under certain conditions, those signals could nudge the cell toward energy-conserving, insulin-sensitizing programs.

Evidence landscape

Evidence is a mix of basic biology, animal studies, and a smaller amount of human data. Human work includes observational studies measuring circulating MOTS-c and looking for associations with metabolic markers.

One example is a 2018 paper that measured plasma MOTS-c in lean and obese individuals and reported that associations with insulin sensitivity surrogates appeared mainly in the lean group. This kind of result is useful as an anchor for what has actually been measured in humans, but it does not establish MOTS-c as a therapy.

Safety reality

As of today, MOTS-c is not an FDA-approved drug. That means there is not a public, regulator-grade safety database that answers basic questions about manufacturing consistency, dosing exposure, adverse event rates, and long-term outcomes.

For any “research peptide” sold online, quality is a first-order safety variable. With mitochondrial-derived peptides, identity and purity matter because minor sequence or impurity differences can change biological behavior.

References

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (2015). https://pubmed.ncbi.nlm.nih.gov/25738459/

Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals (2018). https://pubmed.ncbi.nlm.nih.gov/29593067/

MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (2023). https://pubmed.ncbi.nlm.nih.gov/36761202/

The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress (2018). https://pubmed.ncbi.nlm.nih.gov/29983246/